FAQ

ViroBiome™ is a plant-derived bioactive technology platform designed to reinforce biological interfaces while preserving microbiome balance.

Rather than relying solely on elimination-based approaches, ViroBiome™ supports barrier resilience and targeted enzymatic pathway modulation within the Augmented Hygiene framework.

Its modular architecture enables integration into hygiene, barrier-oriented and preventive systems without disrupting microbial ecosystems or existing industrial processes.

Conventional biocides are designed to eliminate microorganisms broadly, often without distinction between harmful and beneficial species.

ViroBiome™ follows a different paradigm. It is engineered to support biological interface resilience through plant-derived bioactive modulation while preserving commensal microbiomes.

Rather than relying on non-selective eradication, ViroBiome™ is positioned within an Augmented Hygiene approach that emphasizes barrier reinforcement, targeted pathway modulation and microbiome compatibility.

ViroBiome™ is not designed as a conventional virucidal agent.

Its technology is based on plant-derived bioactive modulation that can interfere with specific biological activation pathways involved in viral infectivity at the interface level.

Rather than relying on broad physical destruction, ViroBiome™ is positioned within an Augmented Hygiene approach focused on biological interface reinforcement and microbiome compatibility.

Viruses are fundamental components of global ecosystems. In environmental contexts, they contribute to:

• regulation of microbial populations in oceans and soils
• acceleration of genetic exchange and evolution
• maintenance of biodiversity
• structuring of microbiome dynamics
• participation in major biogeochemical cycles, including carbon and nitrogen cycles

However, ecological presence and infectious risk are distinct considerations.

ViroBiome™ does not aim to “preserve viruses” in pathogenic contexts. Instead, it promotes a balanced approach: managing infectious risk at biological interfaces while recognizing the broader ecological role of viral populations in natural systems.

This perspective aligns with the One Health framework, which considers human, animal and environmental systems as interconnected.

ViroBiome™ is designed as a modular bioactive platform adaptable to multiple interface-based systems.

Primary integration areas include:

Human-focused hygiene systems
• intimate and personal care
• barrier-oriented dermal applications
• selected medical-adjacent supports

Functional materials and treated surfaces
• textiles
• non-woven materials
• surface-compatible formulations

Extended research and development domains include:

Animal interface applications
• dermal and mucosal balance systems

Plant and environmental systems
• plant resilience support
• microbiome-compatible agricultural applications

Controlled or closed environments
• confined systems requiring microbiome-compatible interface management

All applications are developed within regulatory frameworks appropriate to each sector.

ViroBiome™ is based on plant-derived bioactive compounds and microbiome-compatible design principles.

Its technologies are developed using botanical sources and formulation approaches intended to support biological interface resilience while respecting commensal microbial ecosystems.

Rather than replicating conventional chemical disinfection models, ViroBiome™ follows an Augmented Hygiene approach inspired by natural biological mechanisms.

ViroBiome™ is designed to act at the biological interface level.

When integrated into a formulation, it contributes to the formation of a bioactive film that supports barrier reinforcement and localized biological modulation.

Rather than relying on broad elimination mechanisms, ViroBiome™ is engineered to support interface resilience through targeted bioactive interactions compatible with the microbiome.

Its approach focuses on reinforcing biological surfaces upstream of disruption, within an Augmented Hygiene framework.

ViroBiome™ technologies have been evaluated in controlled research models involving representatives of different viral families affecting human, animal and environmental systems.

These include enveloped and non-enveloped viruses studied in vitro under laboratory conditions.

Due to regulatory considerations, detailed viral panels and experimental results are available upon request under confidentiality agreement.

ViroBiome™ is designed using plant-derived bioactive compounds and formulation approaches intended to be biodegradable and compatible with biological systems.

Preliminary safety assessments and laboratory evaluations indicate favorable tolerance profiles in tested models.

The platform is developed within a framework that prioritizes microbiome compatibility, ecosystem respect and alignment with environmental responsibility standards.

Environmental performance depends on formulation context and sector-specific regulatory frameworks.

The One Health framework recognizes the interconnection between human, animal and environmental systems.

ViroBiome™ is developed according to this perspective. Its platform approach is designed to support biological interface resilience while preserving microbiome balance across different domains.

Rather than addressing health challenges in isolation, the technology is structured to be adaptable to human hygiene systems, animal interfaces and environmental applications within appropriate regulatory contexts.

This cross-sector compatibility reflects a One Health-oriented innovation strategy.

Yes. ViroBiome™ technologies are protected by international patent filings covering specific plant-derived bioactive compositions and their structured integration into barrier-oriented systems.

The intellectual property portfolio supports modular deployment across multiple industrial sectors.

Licensing frameworks are structured on a sector-specific basis and are discussed individually with qualified industrial partners.

ViroBiome™ is designed according to microbiome-compatible principles.

Its plant-derived bioactive modules aim to reinforce biological interfaces while preserving the integrity of commensal microbial communities, whether cutaneous, oral or environmental.

Rather than relying on broad-spectrum disruption, the platform follows an Augmented Hygiene approach focused on interface resilience and biological balance.

ViroBiome™ is designed as an interface-oriented bioactive technology.

It is intended to support biological barrier resilience within hygiene and barrier-based systems. It is not positioned as a therapeutic or curative product.

Its integration into formulations aims to reinforce surface-level biological stability in contexts requiring enhanced interface management.

ViroBiome™ modules are designed for formulation compatibility and scalable industrial integration.

They can be incorporated into a wide range of product architectures, including creams, gels, emulsions, coatings, treated textiles and selected material-based systems, subject to sector-specific formulation requirements.

Integration is engineered to occur without structural modification of existing manufacturing workflows.

Yes. ViroBiome™ technologies have been evaluated in controlled laboratory models, including in vitro and ex vivo studies assessing enzymatic modulation, barrier interaction and biological compatibility.

These studies provide preliminary data supporting the platform’s interface-oriented bioactive design.

Detailed experimental protocols and results are available for qualified partners under confidentiality agreement.

ViroBiome™ is not designed as a conventional broad-spectrum biocidal agent.

Its interface-oriented bioactive approach focuses on targeted biological modulation rather than non-selective eradication.

Because it does not rely on classical antimicrobial killing mechanisms, its mode of action differs from traditional resistance-driven paradigms.

However, viral evolution is a complex biological process, and resistance dynamics depend on multiple environmental and biological factors.

Industries in hygiene, health, cosmetics, agri-food, packaging, environmental or aerospace can license the technology for sustainable product innovation.

Strong product differentiation

Natural & biotech-powered innovatio

Clean-label and eco-responsible positioning

Ecosystem protection (microbiomes & biodiversity)

Improved management of contaminated waste

Eligibility for the "One Health Inside™" label

How can I get more information?

Contact us at www.virobiome.com to:

Explore licensing opportunities

Request technical data under NDA

Initiate a co-development or research collaboration

ViroBiome™ is not positioned as a direct substitute for conventional disinfectants in all contexts.

It is designed as a complementary bioactive interface technology, particularly suited to sensitive applications where microbiome compatibility and barrier resilience are prioritized.

Its integration depends on regulatory frameworks, formulation context and specific use cases.

Urbanization exposes populations to higher levels of pollution, particulate matter, surface contact density and environmental stress.

These factors can weaken biological interfaces such as skin and mucosal barriers.

ViroBiome™ is designed to support interface resilience and microbiome balance in high-density, high-exposure environments, within an Augmented Hygiene framework.

Aging is associated with structural changes in biological barriers, including lipid depletion, reduced cellular renewal and microbiome shifts.

ViroBiome™ platform modules are designed to support barrier reinforcement and biological interface stability in aging-sensitive tissues.

Its microbiome-compatible approach aligns with preventive strategies focused on long-term resilience rather than aggressive disruption.

ViroBiome™ is positioned as a bioactive technology platform intended for integration into hygiene, barrier-oriented and material-based systems.

Its regulatory classification depends on the final product category, formulation context and intended use.

All applications are developed within the appropriate regulatory frameworks of each sector and geography.

Yes. ViroBiome™ modules are designed with scalability in mind.

The platform relies on plant-derived bioactive sources and standardized formulation processes compatible with industrial production requirements.

Manufacturing scale-up is structured to align with sector-specific quality and compliance standards.

ViroBiome™ modules are developed as stabilized concentrates suitable for incorporation into various formulation types.

Stability performance depends on formulation composition, storage conditions and application environment.

Technical guidance and compatibility assessments are provided during industrial integration phases.

Partnerships are developed on a sector-specific basis.

ViroBiome™ operates through structured collaboration models that may include licensing, co-development and technology integration agreements.

Intellectual property, deployment scope and industrial alignment are defined individually with qualified partners.